Ever Neuro Pharma GmbH
15
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
26.7%
4 terminated/withdrawn out of 15 trials
63.6%
-22.9% vs industry average
60%
9 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
CERebrolysin In CADASIL
Role: lead
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
Role: lead
Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion
Role: collaborator
Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke
Role: collaborator
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
Role: lead
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Role: lead
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
Role: collaborator
IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE
Role: lead
Cerebrolysin REGistry Study in Stroke
Role: lead
The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery
Role: lead
Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke
Role: collaborator
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
Role: lead
Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.
Role: collaborator
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Role: lead
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
Role: lead
All 15 trials loaded